# US 2009/0269787 A1 · Monoclonal Antibody to CD166 and Method for Production Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269787 A1
- Document ID: US20090269787A1
- Status: Published application
- Kind: A1
- Application number: 12/085,674
- Filed: 2006-11-28
- Published: 2009-10-29
- Earliest claimed: 2005-11-29
- Assignees: Japan Science and Technology Agency; Osaka Prefecture University Public Corporation
- Inventors: Yasuhiro Tsukamoto
- Web page: https://patentgrep.com/patent/US20090269787A1

## CPC

- G01N 33/57585: {involving compounds identifiable in body fluids}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

CD166 is a cell adhesion molecule belonging to an immunoglobulin superfamily that is expressed in an excessive amount on the tumor surface. If an monoclonal antibody specifically binding to the CD166 is obtained, it becomes possible to suppress growth of tumor cells, detect the cells, and supply a therapeutic drug thereto specifically. However, because the CD166 proteins are very similar to each other among mammals, it was not possible to obtain an antibody to human CD166, by immunizing, for example, mice with the human CD166. The antibody was prepared by immunizing mice with a purified avian CD166 protein. The antibody was found to be adsorbed on human and mouse CD166 proteins in vitro as well as in vivo and to have an action to suppress tumor growth in mice.

## Claims

### Claim 1

A monoclonal antibody, characterized by binding to a cell adhesion molecule CD166/ALCAM specifically.

### Claim 2 (depends on 1)

The monoclonal antibody according to claim 1, binding to at least part of the amino acid sequence expressed by SEQ ID No. 1 specifically.

### Claim 3 (depends on 1)

The monoclonal antibody according to claim 1, binding to at least part of the amino acid sequence expressed by SEQ ID No. 2 specifically.

### Claim 4 (depends on 1, 2, 3)

The monoclonal antibody according to any one of claims 1 to 3, wherein the subclass thereof is immunoglobulin G.

### Claim 5 (depends on 1, 2, 3)

A hybridoma, characterized by producing the monoclonal antibody according to any one of claims 1 to 3.

### Claim 6

A method of producing a monoclonal antibody, characterized by purifying the antibodies obtained from mice immunized with a CD166 protein of Phasianidae animal into a monoclonal antibody.

### Claim 7 (depends on 1, 2, 3)

A method of measuring the content of CD166, characterized by using the monoclonal antibody according to any one of claims 1 to 3.

### Claim 8

A cancer diagnosis method, characterized by monitoring progress of cancer, based on the CD166 content in blood.
